Skip to content

A New Theory of Electrophysiological Mechanism of Atrial Fibrillation

A New Theory of Electrophysiological Mechanism of Atrial Fibrillation and Catheter Ablation Therapy for Atrial Fibrillation

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05845034
Acronym
ANTEMAF
Enrollment
100
Registered
2023-05-06
Start date
2023-04-01
Completion date
2025-03-30
Last updated
2024-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

The electrophysiological mechanisms of atrial fibrillation remain disagreements. The goal of this clinical trail is to propose a new electrophysiological mechanism hypothesis of atrial fibrillation(AF),meanwhile, the investigators sought to test the hypothesis that the superposition electrograms (SPEs) recorded during atrial fibrillation could be used as target sites for catheter ablation of atrial fibrillation.

Detailed description

Catheter ablation for atrial fibrillation is a promising therapy, whose success is limited in part by uncertainty in the electrophysiological mechanisms of AF. The investigators recruited 100 subjects including paroxysmal(40%) and persistent (60%) AF. Cases were prospectively treated, in a 2-arm 1:1 design, by ablation SPEs followed by pulmonary vein isolation(PVI) ablation (n=50), or pulmonary vein isolation alone (n =50). All procedures are guided by CARTO (Biosense Webster) electroanatomic mapping system and ablation is performed using open irrigated catheters with contact force (CF) sensing (Thermocool SmartTouch, Biosense Webster). Study Group underwent electroanatomic mapping during AF. Using CARTO to identify areas associated with SPEs. Radiofrequency ablation of the area with SPEs was performed, aiming to eliminate SPEs and convert to sinus rhythm or atrial tachycardia.

Interventions

PROCEDUREPVI + SPEs ablation

electrophysiology substrate mapping is the critical difference between both groups.

PROCEDUREPVI ablation

electrophysiology substrate mapping is the critical difference between both groups.

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing a first-time ablation procedure for AF * Paroxysmal AF will be defined as a sustained episode lasting \> 7 days; Persistent AF will be defined as a sustained episode lasting \> 7 days and less than 1 years; Long-lasting persistent AF will be more than 1 year and less than 5 years. * Patients must be willing and able to comply with all peri-ablation and follow-up requirements. * Patients with atrial fibrillation will to accept the procedure of ablation. * Patients signed the written informed consent for the study. * Patients can endure the required follow up.

Exclusion criteria

* Patients with contraindications to systemic anticoagulation with heparin or a direct thrombin inhibitor. * Patients with thromboembolus in left atrial appendage. * Patients with left atrial size ≥ 55 mm (2D echocardiography, parasternal long-axis view). * Patients allergic for contrast or iodine. * Patients with the serum creatinine(SCr) \>3.5mg/dl * Patients with life expectancy \< 12 months * Patients who are in the period of pregnant

Design outcomes

Primary

MeasureTime frameDescription
Freedom from AF during follow-upone yearAt the one-year follow-up,AF occurring in the first 3 months after the ablation (blanking period) were censored.Beyond this, any AF episode that lasted for more than 30 seconds was categorized as a recurrence.

Secondary

MeasureTime frameDescription
Acute success rate of AF termination during ablation procedureone yearConversion of AF to normal sinus rhythm or atrial tachyarrhythmias during ablation procedure.
Complicationsone yearSerious adverse events included death, pericardial tamponade , cerebrovascular events, significant PV stenosis , left atrial-esophageal fistula.
freedom from documented AF/AT episodeone yearfreedom from any documented AF/AT episode lasting \> 30 s after the blanking period without anti-arrhythmic drugs during the 12-month follow-up after a single procedure.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026